A longevity programme is a testing programme with treatments attached. Which therapy, which dose, whether to do anything at all: all of it rests on what got measured at the start and who read it. That makes the panel the most consequential decision in the programme, and the one patients ask about least.
It is also where the field is least consistent. Two clinics can both call their service longevity medicine while ordering tests with very different amounts of evidence behind them.
Broad screening does not do what it appears to do
The largest body of evidence on general health checks is discouraging. A 2019 Cochrane review by Krogsbøll, Jørgensen and Gøtzsche pooled 17 randomised trials covering 251,891 participants and found that health checks have little or no effect on total mortality (RR 1.00, 95% CI 0.97 to 1.03, high-certainty evidence), on cardiovascular mortality, or on cancer mortality. Its conclusion was blunt: general health checks are unlikely to be beneficial.
That finding is easy to misread in both directions. It does not say testing is pointless. It says that screening a population that has no particular reason to be screened, across a wide panel, does not translate into fewer deaths.
The reason matters more than the headline. A test earns its place when a specific result would change a specific decision. Most items on a broad package do not clear that bar for most people, and every one of them can produce a borderline value that generates follow-up investigations, anxiety and cost without changing anything about how long you live or how well.
So the useful question is never “how many tests does this package include”. It is “which of these would change what you do next”.
What earns a place in the panel
Three cardiovascular markers moved decisively in the 2026 ACC/AHA Guideline on the Management of Dyslipidemia, published in March 2026, and they are the clearest current answer to that question.
Lipoprotein(a). The guideline recommends measuring Lp(a) at least once in every adult’s lifetime, the first time ACC/AHA has recommended universal screening for it. Lp(a) is largely genetic, it does not move much with diet or exercise, and a single measurement tells you whether you are carrying a risk most standard panels never look for.
Coronary artery calcium. CAC scoring was upgraded from a Class 2a to a Class 1 recommendation for risk stratification beyond the PREVENT calculator. It is a non-contrast scan that reports whether calcified plaque is present in your coronary arteries. For someone in the borderline or intermediate risk band, it is the test most likely to change what happens next in either direction.
Apolipoprotein B. The guideline describes apoB measurement as useful in patients with established cardiovascular disease or at high risk, and notes that treatment can reasonably be intensified when apoB is elevated even if LDL-C is already at goal. It counts atherogenic particles rather than the cholesterol inside them, which is why the two can disagree.
Around those sits the unglamorous baseline that answers most of what people actually walk in with: a full blood count, metabolic and liver panel, HbA1c, thyroid function, ferritin, vitamin D and an inflammatory marker. Fatigue, in particular, is far more often iron deficiency, subclinical thyroid dysfunction or poor sleep than anything requiring a regenerative therapy. Reading those results properly is the part of a longevity consultation that most often changes a plan.
What a biological age number is worth
Less than the marketing implies, and more than nothing. Epigenetic clocks estimate age from DNA methylation patterns, and the second- and third-generation versions — PhenoAge, GrimAge, DunedinPACE — do carry real signal in population research, associating with disease and mortality more strongly than earlier clocks did.
Individual results are a different matter. A 2025 review in Epigenomics, “From Population Science to the Clinic? Limits of Epigenetic Clocks as Personal Biomarkers”, concluded that single clock readings are too noisy to be informative for individual clinical decisions. Measurement error, variation between laboratories and platforms, batch effects and biological confounders all sit inside one number. Methylation at individual sites shifts on timescales of minutes to hours. There are no established cut-off values, which is the clinical difference between a biomarker and a curiosity.
The practical position: a biological age result is worth having next to your bloodwork and your history, and worth repeating over years rather than reacting to once. It is not worth treating. If a clinic proposes a protocol because your epigenetic age came back four years high, ask what the same test would read next Tuesday.
The map the field works from
Most of what longevity medicine talks about traces back to one framework. López-Otín and colleagues set out nine hallmarks of aging in Cell in 2013 and expanded them to twelve in 2023: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, disabled macroautophagy, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, altered intercellular communication, chronic inflammation and dysbiosis.
It is a research map, not a treatment menu, and the distinction gets lost in clinic marketing with some regularity. Nobody treats twelve hallmarks. When you see a page listing all twelve with a service attached to each, you are looking at a sales structure borrowing a scientific one.
What to ask before you start
- What decision does this test inform? If the answer is “so we have a baseline”, ask what a baseline changes.
- Who reads the results? A named physician who will still be involved in six months, not a report generated by a lab.
- What would count as this not working? Agreed in advance, in writing, with a date.
- What is included in follow-up, and what costs extra? The second round of testing is where a programme becomes useful and where budgets are usually silent.
- What would make you tell me not to proceed? A clinic with no answer has no screening process.
Where this leaves a visit to Chiang Mai
The measurement half of a programme fits a trip. Bloodwork, imaging and a physician consultation are all straightforward to schedule inside a stay, and Chiang Mai is a practical base for it, quieter than Bangkok, with specialist access and a short list of things to do while you wait for results.
What does not compress is the interval. A single set of numbers describes a moment. The value comes from the second set, months later, read against the first by someone who remembers the plan and is willing to say the plan did not work. Any programme worth flying for should tell you that before you book, not after.
At ARPAR, planning starts with diagnostics and a consultation with Dr. Pattanawadee Uttawichai, and the honest recommendation is sometimes that a treatment is not indicated yet. That is the conversation worth having.
Sources: Krogsbøll LT, Jørgensen KJ, Gøtzsche PC. General health checks in adults for reducing morbidity and mortality from disease. Cochrane Database of Systematic Reviews, 2019 (PMID 30699470) · 2026 ACC/AHA Guideline on the Management of Dyslipidemia (American College of Cardiology) · From Population Science to the Clinic? Limits of Epigenetic Clocks as Personal Biomarkers, Epigenomics, 2025 (PMC12714307) · López-Otín C et al. Hallmarks of aging: An expanding universe. Cell, 2023 (PMID 36599349)